Nurami Medical

Modernizing Soft Tissue Repair

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in April 2014 by Amir Bahar and Nora Nseir, Nurami Medical operates with 11–50 employees. The company has raised $43.65 million across 8 funding rounds from 11 investors. In August 2023, Nurami Medical's ArtiFascia® Dura Substitute received FDA Clearance.

Business overview

Nurami Medical develops advanced bio surgical implants for soft tissue repair, leveraging proprietary nanofiber and novel biomaterial technology. The company's electrospun-based platform creates innovative solutions to seal and heal wounds, addressing complications like leaks and promoting healthy tissue regeneration. Nurami's products, including ArtiFascia, a multilayer dural repair graft with FDA 510(k) clearance, serve the medical devices, biomaterials, and tissue engineering sectors, primarily targeting surgeons and hospitals in markets such as the United States, China, and Europe.

Strategic signal

In November 2025, Nurami Medical announced the successful completion of Phase 1 milestones in an EIC-backed grant for its ArtiFix dural repair graft. This achievement signals continued progress in the development of next-generation regenerative solutions for soft tissue repair, demonstrating the company's commitment to advancing its product pipeline and validating its technology through significant grant funding and development milestones.

Company Intelligence Q&A

What is ArtiFascia?
ArtiFascia is Nurami Medical's first soft-tissue repair product. It is a multilayer, Dural repair graft made of biocompatible and bioabsorbable polymers with an integrated barrier layer and a biomimetic structure of electrospun fibers designed to promote neodura regeneration. ArtiFascia is available for commercial use in the USA and has FDA 510(k) clearance.
When did Nurami Medical receive FDA clearance for ArtiFascia?
In August 2023, Nurami Medical's ArtiFascia® Dura Substitute received FDA Clearance.
What was a key development regarding the ArtiFix dural repair graft?
In November 2025, Nurami Medical announced the successful completion of Phase 1 milestones in an EIC-backed grant for its ArtiFix dural repair graft.
Who led Nurami Medical's Series B funding round in November 2020?
In November 2020, Nurami Medical raised a Series B funding round led by.
When did Nurami Medical receive a grant from the Israel Innovation Authority?
In December 2019, Nurami Medical received a grant from the Israel Innovation Authority.

External links